Source comparison
Oral vs Injectable: Which Causes More Diarrhea?
The administration route is the strongest predictor of whether BPC-157 will cause digestive symptoms. Oral capsules (500+ mcg) Highest (10-25% estimate) Direct GI contact at high concentration Oral capsules (250 mcg) Moderate (5-15% estimate) Lower concentrati
This comparison does not assign a generated winner or score.
- The administration route is the strongest predictor of whether BPC-157 will cause digestive symptoms.
- Oral capsules (500+ mcg)
- Highest (10-25% estimate)
- Direct GI contact at high concentration
- Oral capsules (250 mcg)
- Moderate (5-15% estimate)
- Lower concentration reduces GI activation
- Subcutaneous injection
- Low (<5% estimate)
- Bypasses GI tract; systemic absorption
- Intramuscular injection
- Oral BPC-157 delivers the peptide directly to the intestinal lining, where it interacts with mucosal receptors at full concentration. The GI tract is both the target tissue and the site of side effects. Injectable BPC-157 enters the bloodstream and reaches the gut through systemic circulation at much lower local concentrations.
- If you are taking BPC-157 specifically for gut healing (colitis, leaky gut, NSAID damage), oral administration makes therapeutic sense despite the higher diarrhea risk. The peptide reaches the target tissue directly. If you are using BPC-157 for tendon repair, joint healing, or other non-GI purposes, subcutaneous injection avoids GI side effects entirely. For a detailed comparison, see our BPC-157 oral vs injection guide.